标题/作者	年份
Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area S Richardson, JS Hirsch, M Narasimhan, JM Crawford, T McGinn, ... Jama 323 (20), 2052-2059	2020
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial P Gautret, JC Lagier, P Parola, L Meddeb, M Mailhe, B Doudier, J Courjon, ... International journal of antimicrobial agents 56 (1), 105949	2020
A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19 B Cao, Y Wang, D Wen, W Liu, J Wang, G Fan, L Ruan, B Song, Y Cai, ... New England Journal of Medicine	2020
Dexamethasone in hospitalized patients with Covid-19—preliminary report TRC Group The New England journal of medicine	2020
Endothelial cell infection and endotheliitis in COVID-19 Z Varga, AJ Flammer, P Steiger, M Haberecker, R Andermatt, ... The Lancet 395 (10234), 1417-1418	2020
Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy G Grasselli, A Zangrillo, A Zanella, M Antonelli, L Cabrini, A Castelli, ... Jama 323 (16), 1574-1581	2020
Incidence of thrombotic complications in critically ill ICU patients with COVID-19 FA Klok, M Kruip, NJM Van der Meer, MS Arbous, D Gommers, KM Kant, ... Thrombosis research 191, 145-147	2020
Features, evaluation, and treatment of coronavirus (COVID-19) M Cascella, M Rajnik, A Aleem, SC Dulebohn, R Di Napoli Statpearls [internet]	2022
Temporal dynamics in viral shedding and transmissibility of COVID-19 X He, EHY Lau, P Wu, X Deng, J Wang, X Hao, YC Lau, JY Wong, Y Guan, ... Nature medicine 26 (5), 672-675	2020
Estimates of the severity of coronavirus disease 2019: a model-based analysis R Verity, LC Okell, I Dorigatti, P Winskill, C Whittaker, N Imai, ... The Lancet infectious diseases 20 (6), 669-677	2020
Using social and behavioural science to support COVID-19 pandemic response JJV Bavel, K Baicker, PS Boggio, V Capraro, A Cichocka, M Cikara, ... Nature human behaviour 4 (5), 460-471	2020
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111	2021
The trinity of COVID-19: immunity, inflammation and intervention MZ Tay, CM Poh, L Rénia, PA MacAry, LFP Ng Nature Reviews Immunology 20 (6), 363-374	2020
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial Y Wang, D Zhang, G Du, R Du, J Zhao, Y Jin, S Fu, L Gao, Z Cheng, Q Lu, ... The lancet 395 (10236), 1569-1578	2020
Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19) W Alhazzani, MH Møller, YM Arabi, M Loeb, MN Gong, E Fan, ... Intensive care medicine 46 (5), 854-887	2020
Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review JM Sanders, ML Monogue, TZ Jodlowski, JB Cutrell Jama 323 (18), 1824-1836	2020
Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals A Grifoni, D Weiskopf, SI Ramirez, J Mateus, JM Dan, CR Moderbacher, ... Cell 181 (7), 1489-1501. e15	2020
Compassionate use of remdesivir for patients with severe Covid-19 J Grein, N Ohmagari, D Shin, G Diaz, E Asperges, A Castagna, T Feldt, ... New England Journal of Medicine 382 (24), 2327-2336	2020
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections QX Long, XJ Tang, QL Shi, Q Li, HJ Deng, J Yuan, JL Hu, W Xu, Y Zhang, ... Nature medicine 26 (8), 1200-1204	2020
COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review B Bikdeli, MV Madhavan, D Jimenez, T Chuich, I Dreyfus, E Driggin, ... Journal of the American college of cardiology 75 (23), 2950-2973	2020

1 - 20

计算机程序会自动估算并确定日期和引用次数。